Physician profile
Leslie Couch
NPI 1689663387
$3,867.94
in general payments reported to CMS, 2019-2025
26 companies · $40.58 in 2025
The $40.58 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $691 · 2021: $884 · 2022: $1,425 · 2023: $259 · 2025: $40.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $299.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $668.30 | 2019-2022 | |
| Glaxosmithkline, LLC. | $506.22 | 2020-2022 | |
| Vertex Pharmaceuticals Incorporated | $391.22 | 2019-2025 | Trikafta |
| Philips North America LLC | $261.44 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $245.30 | 2020-2023 | Tagrisso |
| Genzyme Corporation | $169.46 | 2021-2023 | |
| Gilead Sciences, INC. | $165.79 | 2019-2022 | |
| Abbvie INC. | $163.03 | 2019-2023 | Creon |
| Takeda Pharmaceuticals U.S.A., INC. | $152.31 | 2021-2022 | |
| Electromed, INC. | $132.83 | 2021-2023 | Smartvest |
| Mylan Specialty L.P. | $122.62 | 2021-2023 | Tobi Podhaler, Yupelri |
| Advanced Respiratory, INC | $107.27 | 2020-2021 | |
| Genentech USA, INC. | $100.77 | 2021-2022 | |
| Insmed, INC. | $85.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.05 | 2020-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $75.25 | 2022 | |
| Baxter Healthcare | $72.85 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Visivest Airway Clearance System |
| Sunovion Pharmaceuticals INC. | $70.63 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $68.18 | 2021 | |
| Pfizer INC. | $45.54 | 2020-2021 | |
| United Therapeutics Corporation | $42.09 | 2020 | |
| Sanofi-Aventis U.S. LLC | $38.08 | 2019-2020 | |
| Shire North American Group INC | $34.77 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $28.32 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $23.11 | 2022 | |
| Alcresta Therapeutics, INC. | $17.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Couch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.